Head LiceNCT05378477
A Clinical Trial to Evaluate Efficacy and Safety of a New Suffocating Head Lice Product.
A study testing X92001752, RID Super Max Solution and Nix Crème in people with Head Lice and Pediculosis Capitis, run by Oystershell NV at 1 site in United States.
Trial summary
The present study is set-up to compare in vivo clinical performance and safety of the test product (X92001752) versus 3 other pediculicides (2 medical devices and 1 conventional pesticide). Read more about this study
- Who is it for?
- Ages 1 year and olderHealthy volunteers can take part
- Conditions the study is for
- Head Lice, Pediculosis Capitis
- What is being tested?
- X92001752, RID Super Max Solution and Nix Crème
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 220 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Jan 2022to 30 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Gender: male / female.
- Women of childbearing potential is a premenopausal female that is anatomically and physiologically capable of becoming pregnant following menarche.
- Female subjects: are women of childbearing potential who test negative for pregnancy and agree to use a reliable method of birth control or remain abstinent during the study. Methods of contraception considered acceptable include oral contraceptives, contraceptive patch, intrauterine device, vaginal ring, diaphragm with contraceptive gel, or condom with contraceptive gel
- -or are women of non-childbearing potential, defined as: women who have had surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation) or women who are ≥60 years of age.
- Age: ≥ 12 months of age year of age at the time of enrollment.
- Subject must have an active head lice infestation defined as at least 5 live lice (adults and/or nymphs) and 5 apparently live nits, present on the scalp and/or hair, as determined by a trained evaluator.
Show all 17Show fewer
- Subject is in good general health based on medical history.
- The subject or his/her parent/legal guardian (from age 12-17), must give written informed consent, after having been oral and written informed about benefits and potential risks of the trial, as well as information regarding the insurance, taken out to cover the subjects participating in the study. A caregiver must sign an informed consent agreement for children not old enough to do so. Children ages 6-11 years of age will be administered a child's assent form. Subject or his/her parent/legal guardian must be capable of understanding and providing written informed consent.
- Following application and rinsing of the test products, subject agrees not to shampoo, wash, or rinse their hair or scalp until the 24-hour post treatment evaluation has been completed.
- The subject agrees not to cut or chemically treat their hair while participating in the study.
- No more than one working male per household may be excluded from evaluation if he is assessed as being lice free by himself or caregiver.
- Subject agrees to follow all study instructions, including attending all follow-up appointments.
- Agree to not use any other pediculicides or medicated hair grooming products for the duration of the study (through Day 10 visit).
- The parent or legal guardian of a child must be willing to have other family members screened for head lice. If other household members are found to have head lice and are eligible, they must be either enrolled in the study OR receive the standard of care at the site and in the same manner as study participants.
- Have a single place of residence.
- The subject or his/her parent or legal guardian must give written informed consent, after having been oral and written informed about benefits and potential risks of the trial, as well as details of the insurance taken out to cover the subjects participating in the study.
- Subjects must agree to not use any other ant-lice treatment for the duration of the study.
Who cannot join
- 1. Application of any form of head lice treatment, whether prescription or over-the-counter (OTC), or home remedy for 14 days prior to their screening visit (Visit 1).
- Application of any topical medication of any kind on the hair for a period of 48 hours prior to the screening visit.
- 3. Use of systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results.
- 4. Known skin allergies, multiple drug allergies or multiple allergies to cosmetic products.
- 5. History of allergy or hypersensitivity to active ingredients, or constituents of the test products.
- 6. Subject with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test product.
Show all 10Show fewer
- 7. Subjects with chronic scalp disorder. 8. Subject or his/her legal guardian who, in the opinion of the investigative personnel, do not understand the subject requirements for study participations and/or may be likely to exhibit poor compliance with the required visits.
- 9. Females who are pregnant or nursing. 10. Hair longer than mid-back. 11. Subject suspected or known not to follow instructions 12. Previous participation in this study or participation in any other investigational trial within the preceding 14 days.
- 13. The subject is directly affiliated to the investigator site personnel and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- 14. The subject is an Oystershell employee or is an employee of a third-party organizations involved in the study.
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
South Fla. Family Health & Research Ctr.LLC
Plantation, Florida, 33186
About this study
Official title: Randomized, Controlled, Assessor-Blinded, Comparative Study to Evaluate Safety & Efficacy of a New Suffocation Product vs an Oligodecene-based Suffocation Product, 1% Permethrin & a Fatty Acids-based Product in Subjects With Head Lice.
The present study is set-up to compare in vivo clinical performance and safety of the test product (X92001752) versus 3 other pediculicides (2 medical devices and 1 conventional pesticide).
Read the detailed description
The present study is set-up to compare in vivo clinical performance and safety of the test product versus a) RID Super Max Solution (oligodecene oil), Nix crème (1% permethrin), and Pouxit Végétal (fatty acid salts). 220 subjects (n=55 per treatment group) with confirmed diagnosis of head lice infestation will be included. To support safety, local and global tolerability, skin and ocular irritation will be assessed and adverse events (AEs) will be registered.
- Conditions
- Head Lice, Pediculosis Capitis
- Being tested
- X92001752, RID Super Max Solution, Nix Crème, Pouxit Végétal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
X92001752Device
Also called Test product
The test product is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
RID Super Max SolutionDevice
Also called Reference product 1
RID Super Max Solution is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
Nix CrèmeDrug
Also called Reference product 2
Nix crème must be applied on dry hair for 10 minutes and then washed out with water. The product is to be applied on Day 0 and repeated again on Day 7.
Pouxit VégétalDevice
Also called Reference product 3
Pouxit Végétal must be applied on dry hair for 30 minutes and then washed out using shampoo. According to the instructions for use, only 1 treatment must be performed.
| Study group | Role | What they receive |
|---|---|---|
| Test product | Experimental | Hemisqualane \& beeswax-based lotion (X92001752), killing lice and nits via suffocation. Receives: Device: X92001752 |
| RID Super Max Solution | Active comparator | Oligodecene oil-based lotion, killing lice and nits via suffocation. Receives: Device: RID Super Max Solution |
| Nix Crème | Active comparator | Conventional pesticide, containing 1% permethrin. Receives: Drug: Nix Crème |
| Pouxit Végétal | Active comparator | Fatty acid salt-based lotion, killing lice and nits via suffocation. Receives: Device: Pouxit Végétal |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Subjects That Are Lice-free After 2 Treatments With Test Product (Including All Baseline Infestations).
Clinical efficacy is reflected by the % of subjects that are lice-free after 2 topical applications (at day 0 \& day 7 respectively) of the test product. In this analysis, all baseline infestations (mild, moderate, severe) have been included. Assessment is performed at study end (visit 4, day 10).
A mild infestation corresponds to 5-9 lice and/or nymphs A moderate infestation corresponds to 10-24 lice and/or nymphs A severe infestation corresponds to 25 or more lice and/or nymphs
Measured: Day 10
Secondary outcomes (11)
Number of Subjects That Are Lice-free After 2 Treatments With RID Super Max Solution (Including All Baseline Infestations).
Clinical efficacy is reflected by the % of subjects that are lice-free after 2 topical applications (at day 0 \& day 7 respectively) of RID Super Max Solution. In this analysis, all baseline infestations (mild, moderate, severe) have been included. Assessment is performed at study end (visit 4, day 10).
A mild infestation corresponds to 5-9 lice and/or nymphs A moderate infestation corresponds to 10-24 lice and/or nymphs A severe infestation corresponds to 25 or more lice and/or nymphs
Measured: Day 10
Number of Subjects That Are Lice-free After 2 Treatments With Nix crème (Including All Baseline Infestations).
Clinical efficacy is reflected by the % of subjects that are lice-free after 2 topical applications (at day 0 \& day 7 respectively) of Nix crème. In this analysis, all baseline infestations (mild, moderate, severe) have been included. Assessment is performed at study end (visit 4, day 10).
A mild infestation corresponds to 5-9 lice and/or nymphs A moderate infestation corresponds to 10-24 lice and/or nymphs A severe infestation corresponds to 25 or more lice and/or nymphs
Measured: Day 10
Number of Subjects That Are Lice-free After 1 Treatment With Pouxit Végétal (Including All Baseline Infestations).
Clinical efficacy is reflected by the % of subjects that are lice-free after 1 topical applications (at day 0) of Pouxit Végétal. In this analysis, all baseline infestations (mild, moderate, severe) have been included. Assessment is performed at day 7 (last visit).
A mild infestation corresponds to 5-9 lice and/or nymphs A moderate infestation corresponds to 10-24 lice and/or nymphs A severe infestation corresponds to 25 or more lice and/or nymphs
Measured: Day 10
Effect of All Investigational Treatments on Pruritus (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.
The occurrence and degree of pruritus is rated by the blinded clinical investigator at each visit, using the following scores: none (best outcome), mild, moderate, and severe (worst outcome).
None: the scalp does not itch; Mild: occasional episodes of itching, not bothersome; Moderate: frequent, several times a day, bothersome; Severe: nearly constant, frequent scratching, very bothersome.
Measured: Day 0, Day 1, Day 7, Day 10
Effect of All Investigational Treatments on Scalp Excoriation (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.
The occurrence and degree of scalp excoriation (breaking of the skin, usually caused by scratching) is rated by the blinded clinical investigator at each visit, using the following scores: none (best outcome), mild, moderate, and severe (worst outcome).
None: no broken skin on the scalp; Mild: one or two areas on the scalp on which skin is broken; Moderate: more than two separate areas of the scalp with broken skin but not generalized across the scalp; Severe: widespread breaking of the skin involving most of the scalp.
Measured: Day 0, Day 1, Day 7, Day 10
Effect of All Investigational Treatments on Paraesthesia (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.
The occurrence and degree of paraesthesia (tingling or prickling sensation) is rated by the blinded clinical investigator at each visit, using the following scores: none (best outcome), mild, moderate, and severe (worst outcome).
None: no tingling or prickling sensation; Mild: occasional tingling or prickling sensation; Moderate: frequent tingling or prickling sensation; Severe: nearly constant tingling or prickling sensation.
Measured: Day 0, Day 1, Day 7, Day 10
Effect of All Investigational Treatments on Skin Erythema (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.
The occurrence and degree of skin erythema (redness of the scalp) is rated by the blinded clinical investigator at each visit, using the following scores: none (best outcome), mild, moderate, and severe (worst outcome).
None: no redness of the scalp; Mild: faint, barely perceptible erythema with limited distribution; Moderate: diffuse pink areas of scalp are readily visible; Severe: large areas of the scalp are red.
Measured: Day 0, Day 1, Day 7, Day 10
Effect of All Investigational Treatments on Pyroderma (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.
The occurrence and degree of pyroderma (sores filled with clear fluid, pus or crusting) is rated by the blinded clinical investigator at each visit, using the following scores: none (best outcome), mild, moderate, and severe (worst outcome).
None: no lesions visible on the scalp; Mild: one or two lesions visible with crusting or other evidence of infection; Moderate: presence of more than two lesions with crusting or other evidence of infection, but not generalized across the scalp; Severe: lesions with crusting or other evidence of infection, involving most of the scalp.
Measured: Day 0, Day 1, Day 7, Day 10
Effect of All Investigational Treatments on Eye Irritation, as Assessed by a Blinded Clinical Investigator.
The occurrence and degree of eye irritation (stinging, burning sensation, and/or pain) is rated by the blinded clinical investigator at each visit, using the following scores: none (best outcome), mild, moderate, and severe (worst outcome).
None: no stinging, burning or pain Mild: slight mild stinging, burning or pain Moderate: moderate stinging, burning or pain Severe: severe stinging, burning or pain.
Measured: Day 0, Day 1, Day 7, Day 10
Global Tolerability, Evaluated at Study End (Visit 4, Day 10)
Global tolerability is defined as the general well-being and comfort of the subjects. This parameter is assessed at day 10 in subjects, treated with either test product or reference product, respectively. The subject is asked to score his general feeling at study end and must provide a justification for his/her answer. Scoring was performed as follows: very good (best case), good, moderate, or poor (worst case).
Measured: day 10
Assessment of Adverse Events Occurring After 1 and/or 2 Treatments With Both Investigational Products.
Recording Adverse Events and investigating the relationship with the treatment. At each visit (D0: first treatment; D1: 24h post-treatment assessment; D7: second treatment; D10: final assessment), the clinical staff is recording adverse events (if any) and evaluates the correlation with the treatment.
Measured: Study period (10 days) + in case of adverse events: clinical staff will monitor the trial subject's safety from the occurrence of an AE until recovery, return to baseline or a stable state will be achieved.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 May 2022
- Study start17 Jan 2022
- Primary completion30 Sep 2022 (estimated)
- Study completion30 Sep 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Head LiceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 220 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oystershell NV
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Susel Gonzalez Acosta, ARNP, Principal investigator, PI
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05378477
- Sponsor's protocol ID
- OYS008-0020
- Status last verified
- Sep 2022
- First submitted
- 12 May 2022
- Last updated
- 21 Sep 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized, Controlled, Assessor-Blinded, Comparative Study to Evaluate Safety & Efficacy of a New Suffocation Product vs an Oligodecene-based Suffocation Product, 1% Permethrin & a Fatty Acids-based Product in Subjects With Head Lice.
- ClinicalTrials.gov ID
- NCT05378477
- Acronym / sponsor ID
- OYS008-0020
- Conditions
- Head Lice, Pediculosis Capitis
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 220 participants (estimated)
- Lead sponsor
- Oystershell NVIndustry (pharma, biotech, devices)
- Study start
- 17 Jan 2022 (actual)
- Primary completion
- 30 Sep 2022 (estimated)
- Study completion
- 30 Sep 2022 (estimated)
- First posted
- 18 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present study is set-up to compare in vivo clinical performance and safety of the test product (X92001752) versus 3 other pediculicides (2 medical devices and 1 conventional pesticide).
Detailed description
The present study is set-up to compare in vivo clinical performance and safety of the test product versus a) RID Super Max Solution (oligodecene oil), Nix crème (1% permethrin), and Pouxit Végétal (fatty acid salts). 220 subjects (n=55 per treatment group) with confirmed diagnosis of head lice infestation will be included. To support safety, local and global tolerability, skin and ocular irritation will be assessed and adverse events (AEs) will be registered.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Test product | Experimental | Device: X92001752Hemisqualane \& beeswax-based lotion (X92001752), killing lice and nits via suffocation. |
| RID Super Max Solution | Active comparator | Device: RID Super Max SolutionOligodecene oil-based lotion, killing lice and nits via suffocation. |
| Nix Crème | Active comparator | Drug: Nix CrèmeConventional pesticide, containing 1% permethrin. |
| Pouxit Végétal | Active comparator | Device: Pouxit VégétalFatty acid salt-based lotion, killing lice and nits via suffocation. |
Who may qualify
- Ages
- 1 year and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (17 listed)
- Gender: male / female.
- Women of childbearing potential is a premenopausal female that is anatomically and physiologically capable of becoming pregnant following menarche.
- Female subjects: are women of childbearing potential who test negative for pregnancy and agree to use a reliable method of birth control or remain abstinent during the study. Methods of contraception considered acceptable include oral contraceptives, contraceptive patch, intrauterine device, vaginal ring, diaphragm with contraceptive gel, or condom with contraceptive gel
- -or are women of non-childbearing potential, defined as: women who have had surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation) or women who are ≥60 years of age.
- Age: ≥ 12 months of age year of age at the time of enrollment.
Key exclusion criteria (10 listed)
- 1. Application of any form of head lice treatment, whether prescription or over-the-counter (OTC), or home remedy for 14 days prior to their screening visit (Visit 1).
- Application of any topical medication of any kind on the hair for a period of 48 hours prior to the screening visit.
- 3. Use of systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results.
- 4. Known skin allergies, multiple drug allergies or multiple allergies to cosmetic products.
- 5. History of allergy or hypersensitivity to active ingredients, or constituents of the test products.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| X92001752Also: Test productThe test product is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7. | Device | Test product |
| RID Super Max SolutionAlso: Reference product 1RID Super Max Solution is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7. | Device | RID Super Max Solution |
| Nix CrèmeAlso: Reference product 2Nix crème must be applied on dry hair for 10 minutes and then washed out with water. The product is to be applied on Day 0 and repeated again on Day 7. | Drug | Nix Crème |
| Pouxit VégétalAlso: Reference product 3Pouxit Végétal must be applied on dry hair for 30 minutes and then washed out using shampoo. According to the instructions for use, only 1 treatment must be performed. | Device | Pouxit Végétal |
Primary outcome
Number of Subjects That Are Lice-free After 2 Treatments With Test Product (Including All Baseline Infestations).
Time frame: Day 10
Clinical efficacy is reflected by the % of subjects that are lice-free after 2 topical applications (at day 0 \& day 7 respectively) of the test product. In this analysis, all baseline infestations (mild, moderate, severe) have been included. Assessment is performed at study end (visit 4, day 10). A mild infestation corresponds to 5-9 lice and/or nymphs A moderate infestation corresponds to 10-24 lice and/or nymphs A severe infestation corresponds to 25 or more lice and/or nymphs
11 secondary outcomes
Number of Subjects That Are Lice-free After 2 Treatments With RID Super Max Solution (Including All Baseline Infestations).
Time frame: Day 10
Number of Subjects That Are Lice-free After 2 Treatments With Nix crème (Including All Baseline Infestations).
Time frame: Day 10
Number of Subjects That Are Lice-free After 1 Treatment With Pouxit Végétal (Including All Baseline Infestations).
Time frame: Day 10
Effect of All Investigational Treatments on Pruritus (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.
Time frame: Day 0, Day 1, Day 7, Day 10
Effect of All Investigational Treatments on Scalp Excoriation (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.
Time frame: Day 0, Day 1, Day 7, Day 10
Effect of All Investigational Treatments on Paraesthesia (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.
Time frame: Day 0, Day 1, Day 7, Day 10
Effect of All Investigational Treatments on Skin Erythema (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.
Time frame: Day 0, Day 1, Day 7, Day 10
Effect of All Investigational Treatments on Pyroderma (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.
Time frame: Day 0, Day 1, Day 7, Day 10
Effect of All Investigational Treatments on Eye Irritation, as Assessed by a Blinded Clinical Investigator.
Time frame: Day 0, Day 1, Day 7, Day 10
Global Tolerability, Evaluated at Study End (Visit 4, Day 10)
Time frame: day 10
Assessment of Adverse Events Occurring After 1 and/or 2 Treatments With Both Investigational Products.
Time frame: Study period (10 days) + in case of adverse events: clinical staff will monitor the trial subject's safety from the occurrence of an AE until recovery, return to baseline or a stable state will be achieved.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2022.
- Individual participant dataSharing planned: No
Related trials for Head Lice
Recruiting
Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).
Lice; Head Lice
Not yet recruiting
Comparative Study for the Evaluation of a New Medical Device Shampoo on the Treatment of Head Lice Infestation
Headlice
Not yet recruiting
Efficacy and Safetyof a Medical Device With a Physical Mode of Action (X92001919) Versus Paranix Anti-lice Shampoo.
Lice; Head Lice
Recruiting
Safety and Efficacy of Head-lice Treatments Elimax Green Lotion and Walgreens Lice Killing Shampoo
Head Lice
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Susel Gonzalez Acosta, ARNP principal investigator
PI
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing X92001752, RID Super Max Solution and Nix Crème in people with Head Lice and Pediculosis Capitis, run by Oystershell NV at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Elisabeth Rivera, CRD (305-387-0051 ext. 001, sffelisabeth@sffhrc.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Subjects That Are Lice-free After 2 Treatments With Test Product (Including All Baseline Infestations). (time frame: Day 10). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2022.